Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stefan Samuelson

Anesthesiology New York, NY Medical Doctor

NPI 1174787477 CMS profile 1137215

Mount Sinai Roosevelt Department Of Pain Medicine, 1000 10Th Ave, Ste 14A, New York, NY 10019

Open in the dashboard

General payments

$5,615

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stefan Samuelson of New York, NY is reported in the CMS Open Payments database as having received $5,615 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $515 19
2024 General $774 29
2023 General $2,376 33
2022 General $168 7
2021 General $259 7
2020 General $887 11
2019 General $637 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stefan Samuelson
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Stefan Samuelson were reported at $515. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Stefan Samuelson Anesthesiology median Middle half National median
2019 $637 $72 $23–$151 $163
2020 $887 $36 $17–$120 $114
2021 $259 $49 $21–$135 $132
2022 $168 $52 $22–$144 $149
2023 $2,376 $53 $23–$143 $160
2024 $774 $55 $25–$150 $164
2025 $515 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lumenis BE inc $1,687 1 payment
  2. AbbVie, Inc. $759 39 payments
  3. Becton, Dickinson and Company $600 1 payment
  4. Allergan Inc. $318 8 payments
  5. Teva Pharmaceuticals USA, Inc. $288 11 payments
  6. Pfizer Inc. $275 14 payments
  7. Nevro Corp. $261 2 payments
  8. Biodelivery Sciences International, Inc. $246 7 payments
  9. Lundbeck LLC $238 7 payments
  10. Collegium Pharmaceutical, Inc. $190 10 payments
  11. Other $753 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,015 118 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $600 1 payment
Products named General payments · program years 2019–2025
  1. M22 $1,687 1 payment
  2. BD Intelliport $600 1 payment
  3. BOTOX Botox Therapeutic $314 19 payments
  4. NURTEC ODT $275 14 payments
  5. Senza $261 2 payments
  6. ZAVZPRET $256 13 payments
  7. BOTOX Neuroscience $243 12 payments
  8. VYEPTI $238 7 payments
  9. AUSTEDO $192 7 payments
  10. QULIPTA $191 7 payments
  11. Other $1,936 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,157

Median for Anesthesiology: 322

Drug cost

$185,587

Median for Anesthesiology: $8,738

Branded share of claims

31.6%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 21 $52,789
Percocet Oxycodone Hcl/Acetaminophen Brand 13 $52,099
Botox Onabotulinumtoxina Brand 11 $14,151
Belbuca Buprenorphine Hcl Brand 20 $12,513
Aimovig Autoinjector Erenumab-Aooe Brand 16 $12,099
Oxycontin Oxycodone Hcl Brand 24 $11,245
Oxycodone Hcl Generic 196 $5,038
Fentanyl Generic 11 $3,072
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 12 $2,865
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 94 $2,587

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$44,711

Of which drugs: $2,048

Medicare patients

57

Average age 75

Services billed

1,516

39 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 74%
High blood pressure 67%
Diabetes 32%
Ischemic heart disease 25%
Cancer 23%
Depression 23%
Osteoporosis 23%
Chronic kidney disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 40 mg J1030 Office 12 18 $86

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
  • Merz Pharmaceuticals, LLC $132
$132 — —
BOTOX
  • AbbVie, Inc. $131
$131 11 —
UBRELVY
  • AbbVie, Inc. $79
$79 — —
QULIPTA
  • AbbVie, Inc. $66
$66 — —
VYEPTI
  • Lundbeck LLC $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record